2026-09-05
$123M of new funding is targeting healthcare revenue cycle and prior authorization
2 funded companies building into healthcare revenue cycle and prior authorization. The work in scope is what the VP Revenue Cycle owns today.
The funding
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic condi
AusperBio raises $120 million in Series C to advance Hepatitis B therapies towards commercialization →Hire digital employees that do the work across healthcare systems, from patient access to revenue cycle. Record the workflow, map the process, and deploy the right digital employee.
TechNovaTime, Inc. Form D filing →What it means
Capital arriving in a function is a reliable leading indicator. It does not mean the incumbents are wrong, and it does not mean these companies will succeed. It means that within the next few quarters the people who run this work will be asked what their function is doing about it, and the honest answer has to start with where that function actually stands.
So we built the assessment for it. Not a purchase decision, a structured set of questions to take to your own team.